We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




准确评估乳腺癌组织的HER2基因状态

By LabMedica International staff writers
Posted on 10 May 2011
一台全自动系统可容易而准确地评估乳腺癌组织的HER2基因状态。

该系统用优化的即用型HER2荧光原位杂交(FISH)试剂盒和BOND方案产生一致的高质量染色切片。该系统改进了实验室工作流,提高了效率,并使实验室能够迅速响应临床医师和客户的需求。

由徕卡微系统公司(Buffalo Grove, IL, USA; www.leica-microsystems.com)设计的HER FISH系统能检测福尔马林固定、石蜡包埋(FFPE)人乳腺癌组织样本中HER2/neu基因的扩增。徕卡HER2 FISH系统可用于辅助评估拟接受赫赛汀(曲妥珠单抗)治疗的患者。

徕卡HER2 FISH系统的设计目的是容易而准确地评估乳腺癌组织的HER2基因状态,它结合使用了雅培分子有限公司(Des Plaines, IL, USA; www.abbottmolecular.com)提供的金标准PathVysion HER2 FISH探针和业界领先的徕卡BOND自动化平台,从而生成准确的结果,提高诊断把握。

用一组独立样本比较徕卡HER2 FISH系统与雅培的PathVysion HER2 DNA探针试剂盒,结果表明,HER2 FISH系统能得到基本一致的结果。徕卡HER2 FISH系统的结果与临床结果的实际关联尚未得到证实。

Related Links:
Leica Microsystems >> www.leica-microsystems.com
Abbott Molecular Inc. More...
>> www.abbottmolecular.com

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.